The latest cancer research has shown that people with low risk thyroid cancer can receive lower doses of radiation therapy.…
The latest cancer research has shown that people with low risk thyroid cancer can receive lower doses of radiation therapy. (Source: File Photo)
Hospitals can now treat people with low risk of thyroid cancer with a small amount of radioactivity after surgery, according to a recent study. Billed as the world’s longest running trial of low-risk thyroid cancer patients conducted in Britain, the proposed guidelines will, when approved, probably benefit thousands. Dr Jonathan Wadsley, a clinical clinic consultant at Weston Park Hospital in Sheffield and chairman of the Cancer Research Institute (NCRI), subjected to thyroid cancer subgroup, presented the results at the recent 2018 NCRI Cancer Conference in Glasgow.
The latest results showed that there was no significant difference in the recurrent rate of cancer between patients receiving a low dose of radiation compared to the standard higher dose. When patients had lower activity they suffered fewer side effects. They were less likely to feel sick or cause damage to the salivary glands, potentially leading to a permanent dry mouth, found the study. Reduced dose reduces the patient’s chance of getting cancer later.
According to experts, many patients find it hard to stay in the hospital’s isolation room for two to three days without physical contact with friends and relatives when they receive higher doses. When the applied doses are high, radiation protection measures require that the dose drops before the patient is released from the isolation room. Health care saves money when patients get low activity. In addition, hospitals can treat more patients. Radiation protection enthusiasts support patient treatment a lot of radioactivity as low as reasonably achievable without sacrificing clinical benefits.
Researchers at AIIMS, New Delhi, are seen as pioneers in this area. In 1996, AIIMS researchers conducted the first prospective randomized clinical trial for administered dose to destroy residual cells. In addition to the study, there were two other studies from France (ESTIMABL group) and, United Kingdom (HiLo study). The latter two had further follow-up. Although doctors used radioiodine for the treatment of thyroid cancer for decades, it continued to be a mystery.
2014, in a clinical trial of low-risk thyroid cancer published in the British Medical Journal, researchers noted that thyroid cancer is one of the fastest-growing diagnoses, there are more cases of thyroid cancer every year than all leukemias and cancers in the liver, pancreas and stomach. They found that most of these cases are of papillary origin and are small and localized. “Patients with these small localized papillary thyroid cancer have a survival rate of 99 percent at 20 years. Given the good prognosis for these tumors, they have been designated as low fat. The presence of these low-risk thyroid cancer is probably due to the use of imaging technology that can expose a large reservoir of subclinical disease, “they concluded.
The first step in treating thyroid cancer is to remove the thyroid gland surgically. Even an experienced surgeon can leave some cancer cells and thyroid cells on site. Some cells may move away. Doctors want to destroy all remaining normal thyroid and thyroid cancer cells after surgery. If a doctor does not, the remaining cells can proliferate, leading to recurrent cancer later. The cancer specialists administer radioactive iodine (I-131) in liquid or capsule form to avoid this. Radioisotopes concentrate in thyroid cells in the body wherever they are. Radiation emitted from radioiodine destroys remaining thyroid cells after surgery.
Dr Wadsley reported the outcome of 434 patients with low risk thyroid cancer from 29 British hospitals in the HiLo trial with a median (average) follow-up time of 6.5 years. He confirmed to this author that many UK centers have already adopted the low dose regimen to treat patients with low risk of thyroid cancer after publishing the primary outcome of the study back in 2012. “The recently reported long-term follow-up data gives us confidence that the use of it The lower dose does not lead to an increase in prolonged recurrent thyroid cancer, “he claimed. Lancet Diabetes and Endocrinology have accepted the study for publication; It is currently subject to a final editorial review.
According to Dr Martin Forster of University College London, who is chair of the NCRI Head and Neck Clinical Studies Group but not involved in this research, “Nearly seven years of follow-up data from HiLo attempts give us confidence that the lower radiation dose for patients with low risk thyroid cancer is a safe and effective treatment and that international guidelines can be updated to reflect this. For many patients, the treatment and how it is delivered, as well as the short and long term side effects, can have a major impact on their lives. “